Mitoquinone (MitoQ10) mesylate

Catalog No.S8978 Synonyms: MitoQ, Mitoubiquinone

For research use only.

Mitoquinone mesylate (MitoQ, MitoQ10, Mitoubiquinone) is a TPP-based, mitochondria-targeted antioxidant that blocks H2O2-induced intracellular ROS responses and protects against oxidative damage. This product is a waxy solid.

Mitoquinone (MitoQ10) mesylate Chemical Structure

CAS No. 845959-50-4

Selleck's Mitoquinone (MitoQ10) mesylate has been cited by 9 Publications

Purity & Quality Control

Choose Selective ROS Inhibitors

Biological Activity

Description Mitoquinone mesylate (MitoQ, MitoQ10, Mitoubiquinone) is a TPP-based, mitochondria-targeted antioxidant that blocks H2O2-induced intracellular ROS responses and protects against oxidative damage. This product is a waxy solid.
Targets
mitochondria [1] ROS [1]
In vitro

Mitoquinone blocks H2O2-induced intracellular ROS responses inmurine pancreatic acinar cells. Mitoquinone does not reduce mitochondrial depolarisation induced by either cholecystokinin (CCK) or bile acid TLCS. Mitoquinone increases basal and CCK-induced cell death in a plate-reader assay.[1]

In vivo

In a TLCS-induced AP model Mitoquinone treatment is not protective. In AP induced by caerulein hyperstimulation (CER-AP), Mitoquinone exerts mixed effects. Thus, partial amelioration of histopathology scores is observed but without reduction of the biochemical markers pancreatic trypsin or serumamylase. Lungmyeloperoxidase and interleukin-6 are concurrently increased by Mitoquinone in CER-AP. Mitoquinone causes biphasic effects on ROS production in isolated polymorphonuclear leukocytes, inhibiting an acute increase but elevating later levels.[1]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Pancreatic Acinar Cells
  • Concentrations: 1 μM, 10 μM
  • Incubation Time: 200 s, 400 s, 600 s, 800 s, 1000 s
  • Method:

    The cells are loaded with 40 nM TMRM for 30 minutes prior incubation with either 1 μM or 10 μM of MitoQ or dTPP. Cholecystokinin-8 (CCK-8, 10 nM) or bile acid taurolithocholic acid 3-sulphate (TLCS, 500 μM) is used to induce ΔΨm depolarisation. At the end of the perfusion, the protonophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP, 10 μM) is added to induce complete depolarisation of ΔΨm. The fluorescence of TMRM is excited at 543 nm and the emission is collected at 560–650 nm.

Animal Research:

[1]

  • Animal Models: C57BL/6J mice
  • Dosages: 10 mg/kg, 25 mg/kg
  • Administration: IP

Chemical Information

Molecular Weight 678.81
Formula

C38H47O7PS

CAS No. 845959-50-4
Storage 2 years -20°C
Smiles CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)[O-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04109820 Recruiting Dietary Supplement: MitoQ Sickle Cell Disease University of Pittsburgh March 1 2020 Not Applicable
NCT04098510 Unknown status Dietary Supplement: MitoQ Healthy University of Copenhagen September 8 2019 Not Applicable
NCT01167088 Terminated Drug: Mitoquinone mesylate|Drug: Placebo Non-alcoholic Fatty Liver Disease Antipodean Pharmaceuticals Inc. November 2010 Phase 2
NCT00433108 Completed Drug: Mitoquinone mesylate (MitoQ) Chronic Hepatitis C Antipodean Pharmaceuticals Inc. March 2007 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Mitoquinone (MitoQ10) mesylate | Mitoquinone (MitoQ10) mesylate supplier | purchase Mitoquinone (MitoQ10) mesylate | Mitoquinone (MitoQ10) mesylate cost | Mitoquinone (MitoQ10) mesylate manufacturer | order Mitoquinone (MitoQ10) mesylate | Mitoquinone (MitoQ10) mesylate distributor